What is Unlearn.AI?
Founded in 2017 by former Pfizer principal scientist Charles Fisher, Unlearn.AI has established itself as the first company to develop 'digital twins' for use in intelligent control arms within clinical studies. These digital twins are longitudinal, computationally generated clinical records that simulate what would have happened if a patient received a placebo. By integrating data from real patients, Unlearn's technology aims to replace the need for traditional placebo-controlled cohorts, thereby reducing the number of participants required for trials. This innovation not only streamlines the research process but also has the potential to increase study power by decreasing variability and enabling more robust secondary endpoints and exploratory analyses. The company is currently focusing its DiGenesis machine learning platform on diseases with limited treatment options, such as Alzheimer's disease and multiple sclerosis.
How much funding has Unlearn.AI raised?
Unlearn.AI has raised a total of $180M across 5 funding rounds:
Series A
$15M
Other Financing Round
$15M
Multiple Rounds
$150M
Series A (2020): $15M with participation from 8VC, Mubadala Capital Ventures, Eisai, DCVC, and DCVC Bio
Other Financing Round (2023): $15M led by Wittington Ventures and Radical Ventures
Series C (2024): $50M supported by Mubadala, Altimeter Capital, Wittington Ventures, and Radical Ventures
Series C (2024): $50M featuring Mubadala, Altimeter Capital, Wittington Ventures, and Radical Ventures
Series C (2024): $50M backed by Mubadala, Altimeter Capital, Wittington Ventures, and Radical Ventures
Key Investors in Unlearn.AI
Mubadala
Mubadala is a global investment company based in Abu Dhabi, United Arab Emirates, focused on creating sustainable financial returns and diversifying the economy.
Altimeter Capital
Altimeter Capital is an investment firm that partners with technology companies from early growth through public markets, supporting product, strategy, and value creation.
Wittington Ventures
Wittington Ventures is a private Canadian family company with diverse investments, including significant stakes in retail and property sectors.
What's next for Unlearn.AI?
With its substantial recent financing and a clear strategic vision, Unlearn.AI is poised for accelerated growth and market penetration. The company's focus on leveraging AI for digital twins in clinical trials positions it at the forefront of a significant shift in pharmaceutical research methodologies. Future developments are likely to involve expanding the application of its DiGenesis platform to a broader range of therapeutic areas and further refining its predictive capabilities. The strategic backing from prominent investors suggests a commitment to scaling operations, enhancing technological development, and solidifying its position as a leader in AI-driven clinical trial innovation. This capital infusion will be critical in navigating the complex regulatory landscape and demonstrating the value of digital twins to a wider audience of pharmaceutical and biotechnology companies.
See full Unlearn.AI company page
